
jun pm et
summari compani largest pharmaci health care provid
price-to-earnings oper ep
risk assess reflect compani leadership
posit strong market share rel stabl
 retail drug industri off-set acquisition-integr
risk growth non-tradit competitor
aug ep estim base cfra oper earn
histor earn report compani report
dividend paid sinc compani report
past perform indic futur perform
reli upon
forecast reliabl indic futur perform
stk
past perform indic futur perform reli upon
analysi prepar equiti analyst
jun stock trade
expect total sale rise
integr recent acquisit
billion expect net new
partial off-set lower drug price inflat
see store sale rise
benefit sever flu season earli
strong prescript volum growth
greater particip medicar part
network eas comparison
second half health plan network
restrict plan particip store
base
expect ebitda margin narrow
reflect shift busi mix follow
environ reduc drug reimburs
level off-set acquisit synergi
sale gener drug privat label
product help allevi margin
pressur
frozen share repurchas program
await complet aetna acquisit
reduct effect tax rate
see
oper ep oper ep
report exclud
amort intang year
compani agre acquir third
largest health insur aetna aet
total enterpris valu billion
decemb believ combin
expect close second half
make strateg sens provid
greater abil incentiv aet million
health plan particip util caremark
mail order system retail store
complet deal pend approv also
elimin risk lose aet busi
revenu
risk recommend target price
includ greater-than-expect declin
drug reimburs feder state
govern well loss market share
within pbm servic retail pharmaci
target price appli
forward price-to-earnings multipl low end
five-year trade rang
ep estim see
valuat hurt potenti entri new
competitor intens drug reimburs
pressur partial off-set pharmaci benefit
manag busi custom win
expect improv retail
redistribut reproduct prohibit without written permiss copyright cfra document intend provid person invest advic take account specif invest
object financi situat particular need specif person may receiv report investor seek independ financi advic regard suitabl and/or appropri make
invest implement invest strategi discuss document understand statement regard futur prospect may realiz investor note incom
invest may fluctuat valu invest may rise fall accordingli investor may receiv back less origin invest investor seek advic concern impact
invest may person tax posit tax advisor pleas note public date document may contain specif inform longer current use make
invest decis unless otherwis indic intent updat document
corpor overview health corpor oper one largest drug store chain
pharmaci benefit manag base revenu net incom store count drug store offer
prescript drug wide assort gener merchandis includ over-the-counter drug beauti product
cosmet film photo finish servic season merchandis greet card conveni
servic plan design administr formulari manag claim process
market profil oper retail drugstor decemb state
district columbia puerto rico brazil decemb compani store top
 drug store market hold number one number two market share market
fill billion prescript account retail pharmaci
market pharmaci oper critic success view account retail
store sale end privat label brand contribut non-pharmaci sale retail
store
pharmaci servic segment provid full rang pharmaci benefit manag pbm servic
includ oper mail order pharmaci specialti pharmaci medicar part servic
formulari manag discount drug purchas agreement busi gener
billion sale total compani sale exclud interseg elimin
order pharmaci fourmail servic pharmaci
also largest oper retail health care clinic decemb oper
retail health care clinic state minuteclin name clinic diagnos treat
minor health condit perform health screen monitor chronic condit deliv vaccin
compani open new clinic acquir clinic decemb
corpor strategi retail store compani aim improv custom access care
help lower overal health care cost improv health outcom result addit fill
prescript retail pharmacist increas focu provid servic flu
vaccin in-person counsel addit mani possibl interact
custom retail store websit pharmaci servic mail specialti pharmaci
call center compani strive influenc plan member behavior lower cost improv
impact major develop compani acquir pharmaci busi consist
locat in-stor health clinic decemb approxim billion
clinic purchas re-brand minuteclin addit open new clinic within
store end addit plan develop five small format
store two-year period follow close transact
compani acquir omnicar prescript drug servic provid long-term health
specialti healthcar industri total enterpris valu billion august see ep
accret reflect signific synergi revenu purchas improv
compani acquir coram llc specialti infus servic enter nutrit busi apria
healthcar group billion januari
financi trend sale grew compound annual growth rate driven
net new pharmaci servic busi win acquisit low singl digit store sale growth
ebitda margin narrow slightli form reflect increas drug
reimburs pressur nevertheless normal ep grew five-year compound-annual-growth-rate support
share repurchas
execut vice-president chief
offic gener
redistribut reproduct prohibit without prior written permiss copyright cfra
base cfra proprietari quantit model
stock rank overvalu
analysi stock current worth base
cfra proprietari quantit model suggest
under-valued
bullish sinc june technic indic
bullish
figur base fiscal year-end price
growth rate averag
lt debt capit
return equiti
balanc sheet data million
oper
long term debt capit
net incom revenu
return asset
return equiti
 global market intellig data may preliminari restat result discontinu operations/speci item per share data adjust stock dividend ep dilut
redistribut reproduct prohibit without prior written permiss copyright cfra
fundament outlook health care
servic sub-industri next month
neutral think servic includ
rehabilit clinic laboratori
dialysi continu benefit
favor demograph partli offset
increas pressur reduc govern
spend rais possibl medicar
reimburs rate cut possibl
repeal elimin medicaid
expans trump administr
becom neutral dialysi group
view favor patient demograph
off-set reimburs rate pressur
center medicar medicaid servic look
cut expens expect provid see
higher treatment margin due lower drug
cost util howev think
provid still reliant maintain
commerci base rate much
higher offer medicar think
age popul increas focu
prevent care benefit clinic lab
think increas test per requisit
well esoter test lead
remain posit pharmaci benefit manag
pbm see pbm benefit
billion dollar brand drug slate
lose patent protect come year
increas gener drug usag would increas
profit pbm
expect republican administr
continu effort repeal
servic sub-industri larg exposur
medicaid clientel could advers
uncompens care rate could rise
hospit facil would lead
lower profit lower demand health
base index
five-year market price perform jun
gather suffici number vote
pass variou repeal replac bill
republican success elimin
individu mandat passag
tax cut job act decemb
see develop neg
health care servic provid given fewer
custom choos enrol insur
year date march
versu increas
composit index health
servic index increas vs
increas composit
note sector sub-industri inform base
past perform indic futur perform
reli upon
laboratori corpor america
yield equiti
ltd
peer group compani stock select issu base market capit
note peer select base global industri classif standard market capit peer group list includ compani similar characterist may includ compani within
industri and/or engag line busi
redistribut reproduct prohibit without prior written permiss copyright cfra
margin addit debt reduct ahead expect acquisit aetna
et cfra keep hold opinion share aetna inc
keep target price rais ep estim
set stand-alon basi aid
tax reform aet indic acquisit remain
track expect close subject approv ep
vs estim sale declin primarili due
lower membership aet aca-compli individu small group product
aet medic benefit ratio increas bp medic membership
total million decemb /jeffrey loo cfa
et cfra keep buy opinion share group
amazon jp morgan berkshir hathaway announc
partnership form independ healthcar compani serv employe
although time detail compani form still unclear
compani state focu use technolog solut drive
cost past year amazon rumor interest
enter drug distribut market share healthcar compani
express script significantli morn
believ prematur due lack detail time /jeffrey loo
et cfra keep hold opinion share aetna inc
aet agre acquir
consist cash share aet share
deal subject approv expect close although
see anti-trust scrutini believ merger receiv approv
much busi overlap rais target
approxim offer price believ combin pbm unit
increas combin compani leverag better control cost
combin compani sale ebitda /jeffrey loo
analyst research note compani news
et cfra keep buy opinion share
corpor take
larger role on-line pharmaci space agre acquir on-line retail
pillpack today acquisit could provid toehold pharmaci
benefit manag pbm retail drug space howev think
signific size scale provid substanti barrier overcom
potenti disrupt establish industri could take
time believ market initi reaction pillpack
acquisit agreement may overblown /kevin huang cfa
et cfra keep neutral outlook
sub-industri presid trump expect unveil plan
tackl high drug price today believ like focu two area
rebat pharmaci benefit manag pbm get drug firm
discount medicar get scenario believ trump push
portion rebat pbm receiv medicar discount pass
patient anticip trump propos allow medicar negoti
drug price drug firm ban law drug firm blame pbm
signific rise drug price increas rebat
demand pbm hand blame drug manufactur state need
higher rebat discount higher drug list price fda
commission gottlieb indic may examin rebat pbm receiv
potenti kickback potenti medicar negoti tabl
expect share drug firm react favor potenti downward
pressur pbm /jeffrey loo cfa
et cfra keep hold opinion share aetna inc
keep target price base agreed-upon
acquisit term cash share
aet share note final offer price depend share
price close aet expect deal close second half
separ ep vs ahead estim partli
aid tax rate year ago due tax reform sale
rose due membership growth aet medicar product medicar
membership increas aet member march
year ago mainli due declin medicaid
member aet medic benefit ratio improv
partli due reinstat health insur fee /jeffrey loo
et cfra upgrad opinion share corpor
buy hold keep target appli
price-to-earnings near low end five-year rang ep
estim see valuat hurt intens industri
drug reimburs pressur weak in-stor traffic trend despit expect
market share gain increas ep estim
post adjust ep vs estim compar
store sale rose stronger expect driven improv
relationship health plan payor particip greater number
medicar part network despit continu weak foot traffic trend
result see retail prescript trend remain favor rest
expect pharmaci benefit client retent rate
sell season remain line histor level continu expect
merger aetna close year end follow recent approv
sharehold firm /joseph agnes
et cfra keep hold opinion share
corpor rais target
price-to-earnings low end rang ep estim
see valuat pressur industri price pressur
set ep ep vs
estim store sale growth estim benefit
sever flu season plan use tax benefit boost spend
employe data analyt servic offer see pressur
note research note reflect cfra publish opinion analysi stock time note publish note reflect view equiti analyst date time
indic note may reflect cfra current view compani
redistribut reproduct prohibit without prior written permiss copyright cfra
fiscal year analyst estim earn
usd quarter fiscal year
announc earn per share usd repres
total revenu estim fiscal year
analyst estim earn per share grow
usd
total
estimate
forecast reliabl indic futur perform
note compani earn outlook play major part invest decis global market intellig organ earn estim wall street analyst
provid consensu earn next two year well earn estim chang time note inform provid relat consensu
estim intend predict actual result taken reliabl indic futur perform
note tabl graph chart report cite refer sourc sourc global market intellig
redistribut reproduct prohibit without prior written permiss copyright cfra
p/nav price net asset valu ratio price-to-earnings-to-growth ratio pv present
 research develop roce return capit employ roe
return equiti
roi return invest
 return invest capit
roa return asset
wacc weight averag capit
dividend american depositori receipt adr american depositori
share adss net tax paid countri origin
reflect equiti analyst view given compani oper risk
risk firm abil continu on-going concern qualit risk
assess rel rank star univers
reflect risk factor relat compani oper oppos risk
volatil measur associ share price etf reflect
capitalization-weight basi averag qualit risk assess
assign hold fund
star rank system definit
total return expect outperform total return relev benchmark
notabl margin come month share rise price
total return expect outperform total return relev benchmark
come month share rise price absolut basi
total return expect close approxim total return relev
benchmark come month share gener rise price
absolut basi
total return expect under-perform total return relev
benchmark come month share price anticip
total return expect under-perform total return relev
benchmark notabl margin come month share fall
price absolut basi
north america relev benchmark europ
asia relev benchmark europ asia
sinc januari cfra equiti fund research servic
predecessor capit iq equiti research rank univers
common stock adr american depositari receipt adss american
depositari share base given equiti potenti futur perform
similarli rank asian european equiti sinc june
rank equiti accord individu forecast equiti futur total
return potenti versu expect total return relev benchmark
region index asia europ
base time horizon star design meet need
investor look put invest decis perspect data use
assist determin star rank may result analyst
model well intern proprietari model result dynam data
also known
 growth
stabil earn dividend deem key element establish
global market intellig earn dividend rank common stock
design capsul natur record singl symbol
note howev process also take consider certain
adjust modif deem desir establish rank
final score stock measur score matrix determin
analysi score larg repres sampl stock
rang score array sampl align follow
ladder rank
cfra earn per share ep estim reflect analyst project futur
ep continu oper gener exclud variou item
view special non-recur extraordinari also ep estim reflect
either forecast equiti analyst consensu averag ep estim
independ compil global market intellig data
provid cfra among item typic exclud ep estim
asset sale gain impair restructur merger-rel charg legal
insur settlement process research develop expens gain
loss extinguish debt cumul effect account
chang earn relat oper classifi
compani discontinu inclus item stock option
expens recur type charg may vari depend
factor industri practic analyst judgment extent
type data disclos compani
equiti analyst project market price given secur command
month henc base combin intrins rel privat
cfra equiti research produc distribut account research
analyt llc d/b/a cfra cfra us togeth affili
subsidiari cfra certain research produc distribut standard
 poor malaysia sdn bhd cfra malaysia certain research distribut
cfra uk limit cfra uk cfra uk cfra malaysia wholly-own
subsidiari cfra us
abbrevi use equiti research report
ebit earn interest tax
redistribut reproduct prohibit without prior written permiss copyright cfra
